Search Results - "The Lancet (British edition)"
-
1
Hepatocellular carcinoma
Published in The Lancet (British edition) (15-10-2022)“…Summary Hepatocellular carcinoma is one of the most common cancers worldwide and represents a major global health-care challenge. Although viral hepatitis and…”
Get full text
Journal Article -
2
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
Published in The Lancet (British edition) (11-09-2021)“…Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence…”
Get full text
Journal Article -
3
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019
Published in The Lancet (British edition) (17-12-2022)“…Reducing the burden of death due to infection is an urgent global public health priority. Previous studies have estimated the number of deaths associated with…”
Get full text
Journal Article -
4
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Published in The Lancet (British edition) (09-01-2021)“…A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the…”
Get full text
Journal Article -
5
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Published in The Lancet (British edition) (16-01-2021)“…The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with…”
Get full text
Journal Article -
6
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Published in The Lancet (British edition) (08-08-2020)“…Using hearing aids appears to reduce the excess risk from hearing loss. New evidence supports adding three modifiable risk factors—excessive alcohol…”
Get full text
Journal Article -
7
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Published in The Lancet (British edition) (02-04-2022)“…The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine escape and high transmissibility, with early studies indicating lower severity…”
Get full text
Journal Article -
8
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels
Published in The Lancet (British edition) (05-11-2022)“…With advancements in the science of detection and attribution studies, the influence of climate change over many events has now been quantified. Because of the…”
Get full text
Journal Article -
9
Non-alcoholic fatty liver disease
Published in The Lancet (British edition) (05-06-2021)“…Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a…”
Get full text
Journal Article -
10
Gastric cancer
Published in The Lancet (British edition) (29-08-2020)“…Gastric cancer is the fifth most common cancer and the third most common cause of cancer death globally. Risk factors for the condition include Helicobacter…”
Get full text
Journal Article -
11
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
Published in The Lancet (British edition) (23-04-2022)“…Lobectomy is the standard of care for early-stage non-small-cell lung cancer (NSCLC). The survival and clinical benefits of segmentectomy have not been…”
Get full text
Journal Article -
12
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Published in The Lancet (British edition) (28-08-2021)“…First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the…”
Get full text
Journal Article -
13
Psoriasis
Published in The Lancet (British edition) (03-04-2021)“…Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and…”
Get full text
Journal Article -
14
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Published in The Lancet (British edition) (09-10-2021)“…Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). We…”
Get full text
Journal Article -
15
Chronic kidney disease
Published in The Lancet (British edition) (28-08-2021)“…Chronic kidney disease is a progressive disease with no cure and high morbidity and mortality that occurs commonly in the general adult population, especially…”
Get full text
Journal Article -
16
Chronic pain: an update on burden, best practices, and new advances
Published in The Lancet (British edition) (29-05-2021)“…Chronic pain exerts an enormous personal and economic burden, affecting more than 30% of people worldwide according to some studies. Unlike acute pain, which…”
Get full text
Journal Article -
17
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Published in The Lancet (British edition) (19-09-2020)“…Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety…”
Get full text
Journal Article -
18
Liver cirrhosis
Published in The Lancet (British edition) (09-10-2021)“…Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol…”
Get full text
Journal Article -
19
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Published in The Lancet (British edition) (05-12-2020)“…Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to…”
Get full text
Journal Article -
20
Pancreatic cancer
Published in The Lancet (British edition) (27-06-2020)“…Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of…”
Get full text
Journal Article